All In Biotech

NDA 020802 · Haleon US Holdings

Excedrin (Migraine Relief)

Acetaminophen, Aspirin, Caffeine · Oral · Nonsteroidal Anti-inflammatory Drug; Platelet Aggregation Inhibitor; Central Nervous System Stimulant

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Jan 14, 1998

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,695

325 Phase 3, 144 recruiting

FAERS reports

17,178

5,166 serious, 250 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 24, 2026.

Use treats migraine

Therapeutic areas: Neurology · Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 7, 1999 Supplement 2 · Efficacy LetterReviewLabel
  • Jan 14, 1998 Original approval · Type 3 - New Dosage Form Review
1 products under this application
  • EXCEDRIN (MIGRAINE RELIEF) · ACETAMINOPHEN 250MG; ASPIRIN 250MG; CAFFEINE 65MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Acetaminophen" as an intervention, any sponsor and status, largest first.

All 1,695 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,826
  • product use in unapproved indication2,064
  • drug effective for unapproved indication1,573
  • headache1,166
  • nausea1,063
  • fatigue653
  • dizziness618
  • migraine602
  • pain546
  • vomiting533
  • abdominal pain upper511
  • insomnia447

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004675
2005828
2006151
2007119
2008157
2009201
2010217
2011413
2012831
2013347
2014351
2015637
20162,082
20172,150
20181,302
20191,071
2020837
20211,321
2022500
20231,053
20241,067
2025521
2026347

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,612 on PubMed

Sponsor: Haleon US Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.